Tenofovir salvage for nucleoside experienced patients: Muddy waters?

Gut

Volumn 60, Issue 2, 2011, Pages 148-150

  Mutimer, David ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; HEPATITIS B; HUMAN; MONOTHERAPY; NOTE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY;

EID: 78651100387     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.229062     Document Type: Note

References (15)

1. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22.
2. Marcellin P, Chang TT, Lim SG, et al. Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
3. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43:1385-91.
4. Liaw YF, Gane E, Leung N, et al. GLOBE Study Group. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95.
5. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30.
6. Marcellin P, Buti M, Krastev Z, et al. Three years of tenofovir disoproxil fumarate treatment in HBeAg-negative patients with chronic hepatitis B (study 102); preliminary analysis. Hepatology 2009;50:abstract 481.
7. Heathcote EJ, Gane EJ, De Man RA, et al. Three years of tenofovir disoproxil fumarate treatment in HBeAg-positive patients with chronic hepatitis B (study 103); preliminary analysis. Hepatology 2009;50:abstract 483.
8. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
10. Patterson SJ, Geroge J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011;60:247-54.
11. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010;139:1207-17.
12. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008;48:747-55.
13. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-8. (Pubitemid 40770292)
14. Van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80.
15. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 2009;50:1064-71.